One of humankind’s greatest fears is permanent vision loss.1 That’s why we are fearless in the fight against vision loss and committed to moving the field forward.
We are leading the way in complement science and believe that targeting C3 has the potential to address some of the most challenging retinal diseases that patients face. Using this approach, we delivered the first-ever treatment for geographic atrophy, a leading cause of blindness worldwide and a complex disease that the field has spent decades working to address.
We deeply care about the needs of people living with debilitating retinal diseases. By listening and learning in our interactions with patients, caregivers, and patient advocacy groups, we are able to champion the patient voice throughout the drug development process.
Geographic Atrophy (GA)
GA is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss, which impacts ~five million people worldwide.Learn more >>
- Scott AW, Bressler NM, Ffolkes S, Wittenborn JS, Jorkasky J. Public attitudes about eye and vision health. JAMA Ophthalmol. 2016;134(10):1111-1118.